References |
1 |
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
|
2 |
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
|
3 |
New Insights into SN-38 Glucuronidation: Evidence for the Important Role of UDP Glucuronosyltransferase 1A9
|
4 |
Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors
|
5 |
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
|